Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer

被引：11

作者：

Montero, M. Angeles ^{[1
]}

Aricak, Ozan ^{[2
]}

Kis, Lorand ^{[3
]}

Yoshikawa, Akira ^{[4
,5
]}

De Petris, Luigi ^{[3
,6
]}

Grundberg, Oscar ^{[6
]}

Pham, Hoa H. N. ^{[4
]}

Roden, Anja C. ^{[7
]}

Fukuoka, Junya ^{[4
,5
]}

Attanoos, Richard ^{[8
]}

Guijarro, Ricardo ^{[9
]}

Alarcon, Felix ^{[3
]}

Lindstrom, Kati ^{[10
]}

Ortiz-Villalon, Cristian ^{[2
,3
]}

机构：

[1] Manchester Univ NHS Fdn Trust, Dept Histopathol, Manchester, Lancs, England

[2] Karolinska Univ Hosp, Dept Pathol & Cytol, Stockholm, Sweden

[3] Karolinska Inst, Dept Oncol Pathol Onkpat, Stockholm, Sweden

[4] Nagasaki Univ, Dept Pathol, Grad Sch Biomed Sci, Nagasaki, Japan

[5] Kameda Med Ctr, Dept Pathol, Kamogawa, Japan

[6] Karolinska Univ Hosp, Thorac Oncol Ctr, Theme Canc, Stockholm, Sweden

[7] Mayo Clin, Dept Pathol & Lab Med, Rochester, MN USA

[8] Cardiff Univ Hosp, Dept Pathol, Cardiff, Wales

[9] Univ Valencia, Dept Surg, Valencia, Spain

[10] KTH Royal Inst Technol, Div Hist Sci Technol & Environm, Stockholm, Sweden

来源：

ANNALS OF DIAGNOSTIC PATHOLOGY | 2021年 / 51卷

关键词：

Lung cancer and immunotherapy; Predictive biomarkers in non-small cell lung; cancer; PD-L1 status in tumor cells; SQUAMOUS-CELL; IMMUNOHISTOCHEMISTRY; BIOMARKERS; NIVOLUMAB; DOCETAXEL;

D O I：

10.1016/j.anndiagpath.2021.151701

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Introduction: PD1/PD-L1 pathway targeting therapies are nowadays an established treatment option for patients with NSCLC. We assessed whether PD-L1 expression in NSCLC tumor cells was associated with specific clinical features or overall survival using four different clones. Methods and results: A retrospective study included formalin-fixed paraffin embedded (FFPE) surgical tumors from 482 patients. PD-L1 status was assessed with immunohistochemistry in tumor cells on tissue microarrays using clones 28-8, 22C3, SP263 and SP142. Associations with OS were assessed by Kaplan-Meier and multivariate Cox?s regression analysis. Patients? median age: 68 years (39?86); histology: adenocarcinoma (AdCa) 61%, squamous-cell carcinoma (SqCC) 33%, and large cell carcinoma (LCC) 6%; p-stage: IA (46%), IB (30%), IIA (10%), IIB (11,4%), IIIA (1,2%), IIIB ? IV (0,4%). PD-L1 positivity (?1%) in NSCLC for clones 28-8, 22C3, SP263, SP142 was 41.5%, 34.2%, 42.7%, 10.4%, respectively (Pearson Chi-square p < 0.0001). PD-L1 expression was correlated with histology, tumor size and grading. Statistically significant association between PD-L1 expression and OS in NSCLC and Non-AdCa was observed with clone SP142 (log-rank p = 0.045 and p = 0.05, respectively). Statistically significant association between PD-L1 expression and OS in LCC was observed with clones 22C3 (log-rank p = 0.009) and SP263 (log-rank p = 0.050). Conclusions: Overexpression of the PD-L1 clone SP142 was associated with poor overall survival in NSCLC and Non-AdCa. Clones 22C3 and SP263 were associated with poor prognosis in LCC. PD-L1 status might serve as a prognostic marker in NSCLC.

引用

页数：8